ArticleCurrent medical imaging2026
Glymphatic System Alterations in Lung Cancer Patients with Chemotherapy-Related Cognitive Impairment
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChemotherapy-related cognitive impairment (CRCI) is a common adverse effect among lung cancer patients undergoing chemotherapy. Glymphatic system dysfunction has been implicated in the pathogenesis of cognitive deficits. This study aimed to investigate the impact of chemotherapy on the glymphatic system in patients with non-small cell lung cancer (NSCLC) and its association with cognitive outcomes.
methodsA total of 102 NSCLC patients, including 53 patients without chemotherapy (CT(-)), 49 patients with chemotherapy (CT(+)), and 56 healthy controls (HCs), were enrolled. Glymphatic function was assessed using the diffusion tensor image analysis along the perivascular space (DTIALPS) index and choroid plexus (CP) volume. Group differences and correlations with neurocognitive performance were examined.
resultsSignificant differences in the DTI-ALPS index and CP volume were observed among the three groups. Post-hoc analyses revealed that the CT(+) group had significantly lower DTI-ALPS indices and larger CP volumes than both the CT(-) and HCs (p < 0.05). The DTI-ALPS index was positively correlated with MoCA scores (r = 0.448, p = 0.001), while CP volume was negatively correlated with MoCA scores (r = -0.435, p = 0.002). Moreover, the DTI-ALPS index partially mediated the relationship between CP volume and MoCA scores (mediation effect = 32.79%). DISCUSSION: The DTI-ALPS index and choroid plexus (CP) volume serve as comprehensive metrics for assessing global glymphatic function. Previous studies have found that chemotherapy has differential effects on the structure and function of various brain regions, including the hippocampus and prefrontal cortex.
conclusionThis study provides novel insights into the neural mechanisms underlying CRCI in NSCLC patients, highlighting the role of reduced DTI-ALPS index and enlarged CP volume in CRCI pathogenesis. These findings suggest that glymphatic metrics may serve as potential biomarkers for CRCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.